- Home
- IONS vs CRNX Comparison
IONS vs CRNX Comparison
Compare IONS & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CRNX
- Stock Information
- Founded
- IONS 1989
- CRNX 2008
- Country
- IONS United States
- CRNX United States
- Employees
- IONS N/A
- CRNX N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- IONS Health Care
- CRNX Health Care
- Exchange
- IONS Nasdaq
- CRNX Nasdaq
- Market Cap
- IONS 6.0B
- CRNX 5.2B
- IPO Year
- IONS 1991
- CRNX 2018
- Fundamental
- Price
- IONS $30.17
- CRNX $33.54
- Analyst Decision
- IONS Buy
- CRNX Strong Buy
- Analyst Count
- IONS 19
- CRNX 12
- Target Price
- IONS $59.24
- CRNX $73.36
- AVG Volume (30 Days)
- IONS 1.5M
- CRNX 928.6K
- Earning Date
- IONS 05-06-2025
- CRNX 05-08-2025
- Dividend Yield
- IONS N/A
- CRNX N/A
- EPS Growth
- IONS N/A
- CRNX N/A
- EPS
- IONS N/A
- CRNX N/A
- Revenue
- IONS $705,138,000.00
- CRNX $1,039,000.00
- Revenue This Year
- IONS N/A
- CRNX $394.51
- Revenue Next Year
- IONS $25.71
- CRNX $699.82
- P/E Ratio
- IONS N/A
- CRNX N/A
- Revenue Growth
- IONS N/A
- CRNX N/A
- 52 Week Low
- IONS $29.61
- CRNX $31.65
- 52 Week High
- IONS $52.34
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- IONS 37.05
- CRNX 41.58
- Support Level
- IONS $31.04
- CRNX $32.90
- Resistance Level
- IONS $33.76
- CRNX $35.26
- Average True Range (ATR)
- IONS 1.16
- CRNX 1.51
- MACD
- IONS -0.30
- CRNX 0.15
- Stochastic Oscillator
- IONS 10.92
- CRNX 39.38
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.